Molecular Mechanisms and Diagnostic Innovations in HPV-Associated Head and Neck Squamous Cell Carcinomas: Insights into Integration, Epigenetic Modifications, and Biomarker Applications DOI Creative Commons
Geetha Shanmugam, Gnanaprakash Jeyaraj, Koustav Sarkar

et al.

Oral Oncology Reports, Journal Year: 2024, Volume and Issue: 13, P. 100710 - 100710

Published: Dec. 27, 2024

Language: Английский

Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use DOI Creative Commons
Yu Zhang,

Ke Qiu,

Jianjun Ren

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: Jan. 24, 2025

Abstract Human papillomaviruses, particularly high-risk human have been universally considered to be associated with the oncogenesis and progression of various cancers. The genome papillomaviruses is circular, double-stranded DNA that encodes early late proteins. Each proteins crucial significance in infecting epithelium host cells persistently supporting viral integrating into cells. Notably, E6 E7 proteins, classified as oncoproteins, trigger incidence cancers by fostering cell proliferation, hindering apoptosis, evading immune surveillance, promoting invasion, disrupting balance cellular metabolism. Therefore, targeting decoding molecular mechanisms which drive carcinogenesis are great necessity better treat papillomaviruses-related applied clinically different facets papillomavirus-related cancers, including prevention, screening, diagnosis, treatment, prognosis. Several types prophylactic vaccines publicly utilized worldwide greatly decreased occurrence benefited numerous people. Although therapeutic developed tested clinically, none them officially approved date. Enhancing efficacy searching for innovative technologies remain critical challenges warrant continuous research attention future.

Language: Английский

Citations

6
SMAC-armed oncolytic virotherapy enhances the anticancer activity of PD1 blockade by modulating PANoptosis DOI Creative Commons
Fanghui Chen, Liwei Lang, Jianqiang Yang

et al.

Biomarker Research, Journal Year: 2025, Volume and Issue: 13(1)

Published: Jan. 9, 2025

Language: Английский

Citations

2
Head and neck tumor organoid biobank for modelling individual responses to radiation therapy according to the TP53/HPV status DOI Creative Commons
Christian Issing, Constantin Menche,

M. Richter

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)

Published: March 5, 2025

Head and neck cancers (HNC) represent an extremely heterogeneous group of diseases with a poorly predictable therapy outcome. Patient-derived tumor organoids (PDTO) offer enormous potential for individualized testing better mechanistic understanding the main HNC drivers. Here, we have established comprehensive molecularly functionally characterized head organoid biobank (HNOB) recapitulating clinically relevant subtypes TP53 mutant human papillomavirus type 16 (HPV 16) infection-driven HNC. Organoids were exposed to radiotherapy, responses correlated clinical data. Genetically engineered normal used direct functional consequences TP53-loss HPV infection. The HNOB consisting 18 models, including 15 was generated. We identified subtype-associated transcriptomic signatures pathological features, sensitivity stabilization by MDM2 inhibitor Nutlin-3. Furthermore, describe in vitro radio response assay revealing phenotypic heterogeneity linked individual patient's treatment outcome, relapse probability. Using genetically organoids, possibility co-existence both cancer drivers confirmed. loss, as well HPV, increased growth organoids. loss-of-function alone insufficient promote radiation resistance, whereas oncogenes E6/E7 mediated radiosensitivity via induction cell cycle arrest. Our results highlight translational value models not only patient stratification but also validation responsiveness specific

Language: Английский

Citations

1
Head and neck cancer: pathogenesis and targeted therapy DOI Creative Commons
Yan Liu, Nannan Zhang,

Yi Wen

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(9)

Published: Aug. 21, 2024

Head and neck cancer (HNC) is a highly aggressive type of tumor characterized by delayed diagnosis, recurrence, metastasis, relapse, drug resistance. The occurrence HNC were associated with smoking, alcohol abuse (or both), human papillomavirus infection, complex genetic epigenetic predisposition. Currently, surgery radiotherapy are the standard treatments for most patients early-stage HNC. For recurrent or metastatic (R/M) HNC, first-line treatment platinum-based chemotherapy combined antiepidermal growth factor receptor cetuximab, when resurgery radiation therapy not an option. However, curing remains challenging, especially in cases metastasis. In this review, we summarize pathogenesis including changes, abnormal signaling pathways, immune regulation mechanisms, along all potential therapeutic strategies such as molecular targeted therapy, immunotherapy, gene modifications, combination therapies. Recent preclinical clinical studies that may offer future research on also discussed. Additionally, new targets methods, antibody-drug conjugates, photodynamic radionuclide mRNA vaccines, have shown promising results trials, offering prospects

Language: Английский

Citations

7
HPV integration in head and neck cancer: downstream splicing events and expression ratios linked with poor outcomes DOI Creative Commons
Shiting Li,

Shaomiao Xia,

Maria Lawas

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Abstract HPV integration (HPVint) is associated with carcinogenesis and tumor progression in HPV-associated cancers, including head neck squamous cell carcinomas (HNSCC). While its impact on human DNA has been well characterized, relationship clinical outcomes remains unconfirmed. Here we investigate the consequences of HPVint both respect to characteristics by analyzing 261 HNSCC bulk single-cell RNA-seq samples from five cohorts, events 102 HPV+ participants two cohorts. By leveraging this large meta-cohort, first reveal an oncogenic network based recurrent locations HNSCC. We then classify HPVint-positive (HPVint(+)) RNA features, specifically spliced HPV-human fusion transcripts ratios gene transcripts, showing that subsets have worse outcomes. Our analyses, focused mainly instead DNA, expand our understanding carcinogenic mechanisms HPVint, partially addressing conflicting findings whether aggressive phenotypes consequences, provide potential biomarkers advance precision oncology

Language: Английский

Citations

0
HPV and Cervical Cancer—Biology, Prevention, and Treatment Updates DOI Creative Commons
Emilia Włoszek,

Katherine Krupa,

Eliza Skrok

et al.

Current Oncology, Journal Year: 2025, Volume and Issue: 32(3), P. 122 - 122

Published: Feb. 22, 2025

One of the most significant breakthroughs in cancer research has been identification persistent infection with certain human papillomaviruses (HPV) genotypes as cause cervical cancer. Since then, a range diagnostic and therapeutic methods developed based on this discovery. This article aims to describe latest updates biology, prevention, treatment HPV-related The current state knowledge regarding vaccinations, tests, therapies is presented. WHO guidelines vaccinations are presented, well announcements upcoming changes. final part summarizes promising new methods, perspectives findings self-administered use vaccines, circulating cell-free DNA diagnosis. Despite progress made recent years, strategy vaccination testing remains cornerstone fight against

Language: Английский

Citations

0
HPV-driven cancer: from epidemiology to the HPV-driven tumor board proposal, everything you wanted to know but were afraid to ask DOI
Daniela Alterio,

Michał Gola,

Mattia Zaffaroni

et al.

Clinical & Translational Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: March 6, 2025

Language: Английский

Citations

0
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers DOI
D. Manikandan, Sankar Jagadeeshan, Sooraj Mathukkada

et al.

Neoplasia, Journal Year: 2025, Volume and Issue: 63, P. 101157 - 101157

Published: March 20, 2025

Language: Английский

Citations

0
Head and neck cancers: Current status preclinical research DOI
Pralhad Wangikar,

M. Sandhya,

Pradhnya Choudhari

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 69 - 94

Published: Jan. 1, 2025

Language: Английский

Citations

0
E5 Oncoprotein: A Key Player in Human Papillomavirus-Positive Head and Neck Cancer Pathogenesis and Therapy Resistance DOI Creative Commons
Vanessa Emanuelle Pereira Santos, Bianca de França São Marcos, Pedro Henrique Bezerra Fontes

et al.

Viruses, Journal Year: 2025, Volume and Issue: 17(4), P. 512 - 512

Published: April 1, 2025

Head and neck cancer (HNC) is the sixth most prevalent type of worldwide associated with low five-year survival rates. Alcoholism smoking are main risk factors development head (HNC). However, Human Papillomavirus (HPV) infection has been reported as a significant factor, particularly for oropharyngeal subset. In these cases, patients HPV-positive HNC exhibit better clinical prognosis; however, resistance to chemotherapy frequently reported. The carcinogenic activity HPV related viral oncoproteins E5, E6, E7. E5 immune evasion mechanisms modulation tumor microenvironment, which appears be linked virus’s chemotherapeutic treatments. Here, we review potential in targeted therapy discuss relevant data regarding this oncoprotein carcinogenesis.

Language: Английский

Citations

0